All our products & solutions for lipid-based drug delivery at a glance
Tiny Carriers, Big Impact: Lipid Nanoparticles for Nucleic Acid Delivery
Lipid nanoparticles (LNPs) are the gold standard for delivering nucleic acids such as RNA into cells. They protect the fragile RNA from degradation, facilitate cellular uptake, and ensure efficient release inside the target cells. LNPs are composed of multiple lipid types that work together to encapsulate and deliver nucleic acids safely and effectively.
Typical Composition of a Lipid Nanoparticle (LNP)
A standard LNP formulation includes:
- Ionizable Cationic Lipid (~50%) – complexes nucleic acids and facilitates endosomal escape
- Structural Lipid (~10%) – ensures particle stability (e.g., DSPC, DOPE)
- Cholesterol (~38.5%) – enhances encapsulation and transfection efficiency
- PEG Lipid (~1.5%) – stabilizes particles and controls size
- Nucleic Acid Payload – the therapeutic RNA
Benefits of Lipid-Based Delivery Systems
Lipid-based systems offer several advantages:
- Improved safety and reduced toxicity
- Targeted delivery and controlled release
- Enhanced bioavailability and intracellular delivery
- Biocompatibility and reduced immune response
- Established design principles and manufacturing techniques
These benefits make lipid-based carriers ideal for a wide range of therapeutic applications, from small molecules to complex biologics.
Your Partner Across the mRNA-LNP Value Chain
Evonik is a fully integrated development partner for nucleic acid-LNP therapeutics, offering:
- Excipient supply (e.g., plant-derived cholesterol, PEG lipids)
- Formulation development using advanced mixing technologies
- Clinical and commercial manufacturing at GMP-certified sites
- Analytical and regulatory support
With over 30 years of experience in lipid-based drug delivery and more than 100 LNP projects, Evonik supports clients from concept to commercialization.
Upcoming events
Stories
